How has been the historical performance of Gufic BioScience?

Answer:The historical performance of Gufic BioScience shows a mixed trend in its financial metrics for the fiscal year ending March 2025 compared to March 2024.

Breakdown:
Gufic BioScience reported net sales of 819.81 Cr in March 2025, a slight increase from 806.67 Cr in March 2024. Total operating income also rose to 819.81 Cr from 806.67 Cr. However, total expenditure increased to 685.12 Cr from 660.79 Cr, leading to a decrease in operating profit (PBDIT) to 138.32 Cr from 148.06 Cr. Profit before tax fell to 94.14 Cr from 115.67 Cr, and profit after tax decreased to 69.65 Cr from 86.14 Cr. The earnings per share (EPS) declined to 6.94 from 8.59, reflecting a decrease in profitability. The operating profit margin and PAT margin also showed a downward trend, with the operating profit margin falling to 16.43% from 18.08% and the PAT margin decreasing to 8.5% from 10.68%. On the balance sheet, total liabilities remained at 1,092.54 Cr, while total assets were unchanged, indicating stability in the company's financial structure. Cash flow from operating activities was negative at -7.00 Cr, with a net cash outflow of 27.00 Cr, highlighting challenges in cash generation. Overall, while Gufic BioScience experienced growth in sales, profitability metrics and cash flow indicate areas of concern.